Postoperative PainNCT04341948
Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System
A study testing SPRINT Peripheral Nerve Stimulation (PNS) System in people with Postoperative Pain and Total Knee Replacement, run by SPR Therapeutics, Inc. at 10 sites in United States.
Trial summary
The purpose of this study is to gather information about how knee pain changes when small amounts of electricity are delivered to the nerves in the leg. This study will involve the use of a Peripheral Nerve Stimulation (PNS) System that is made by SPR Therapeutics (the sponsor of the study). Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty
- What is being tested?
- SPRINT Peripheral Nerve Stimulation (PNS) System
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 56 participants
- Where
- 10 sitesUnited States
- Study dates
- 6 Aug 2020to 27 Jun 2024
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- At least 21 years old
- Underwent a 1. primary total knee replacement (TKR), 2. secondary/revision TKR or 3. Partial/unicompartmental knee replacement (PKR)
- Knee pain directly resulting from Knee Replacement surgery in affected knee
Who cannot join
- Current high opioid use
- Body Mass Index (BMI) > 40 kg/m2
- Conditions with increased risk of infection
- Implanted electronic device
- History of bleeding or clotting disorder.
- Uncontrolled Diabetes Mellitus Types I or II
- Pregnancy
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
United States10 sites
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
Duke University
Durham, North Carolina, 27710
NorthShore University HealthSystem
Evanston, Illinois, 60201
The Orthopaedic Institute
Gainesville, Florida, 32607
Ali K. Valimahomed MD PLLC
Holmdel, New Jersey, 07733
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Ochsner Clinic Foundation
New Orleans, Louisiana, 70115
Better Health Clinical Research, Inc
Newnan, Georgia, 30265
UT Health San Antonio
San Antonio, Texas, 78229
University of California San Diego
San Diego, California, 92103
About this study
Official title: Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System in a Randomized, Double-Blinded, Placebo-Controlled Trial
The purpose of this study is to gather information about how knee pain changes when small amounts of electricity are delivered to the nerves in the leg. This study will involve the use of a Peripheral Nerve Stimulation (PNS) System that is made by SPR Therapeutics (the sponsor of the study). The SPRINT PNS System was cleared by the FDA for up to 60 days of use in the back and/or extremities for the management of acute and chronic pain.
- Conditions
- Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty, Partial Knee Replacement
- Being tested
- SPRINT Peripheral Nerve Stimulation (PNS) System
- Keywords
- Pain, Postoperative, Musculoskeletal Diseases, Postoperative Complications, Nervous System Diseases, Pain, Neurologic Manifestations, Signs and Symptoms
- Medical subject headings
- Pain, Postoperative, Musculoskeletal Diseases, Postoperative Complications, Nervous System Diseases, Pain, Neurologic Manifestations, Signs and Symptoms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SPRINT Peripheral Nerve Stimulation (PNS) SystemDevice
Also called SPRINT, SPRINT System
The SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called "Leads") that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
| Study group | Role | What they receive |
|---|---|---|
| Group 1 (Treatment) | Active comparator | Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks. Receives: Device: SPRINT Peripheral Nerve Stimulation (PNS) System |
| Group 2 (Control) | Sham comparator | Participants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy. Receives: Device: SPRINT Peripheral Nerve Stimulation (PNS) System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction in Average Pain Intensity: Number of Participants With ≥ 50% Reduction in Average Pain Intensity
All participants were asked to complete daily diaries to record their average knee pain during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The average pain scores were calculated across the 7-day diary(s) at baseline and across weeks 5 to 8 post-start of treatment. Percent reduction was then calculated for each participant. To be considered a success, participants must have experienced ≥ 50% reduction in average knee pain. The number of successes is presented.
Measured: Baseline and 5 to 8 weeks post-Start of Treatment (SOT)
Study-Related Adverse Device Effects
At each study visit following the baseline assessment at Visit 1, participants were questioned if any changes in their medical status or condition have occurred since their previous visit. If the participant experienced a change that was a study-related adverse event, an Adverse Event Form was completed by the site. The number of participants that experienced at least one study-related adverse event is reported here. Adverse Events are reported by the trial phase in which they occurred: Group 1 Treatment (active stimulation), Group 2 Control (sham stimulation), and Group 2 Crossover Safety Set (active stimulation).
Measured: Up to 13 months for each Group 1 participant and up to 16 months for Group 2 participants that opted to cross over (time from baseline to last study visit)
Secondary outcomes (9)
Reduction in Average Pain Intensity: Number of Participants With ≥ 50% Reduction in Average Pain Intensity
All participants were asked to complete daily diaries to record their average knee pain intensity during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The average pain score was calculated across the 7-day diary(s) at baseline and across weeks 1 to 4 post-start of treatment. Percent reduction was then calculated for each participant. To be considered a success, participants must have experienced ≥ 50% reduction in average knee pain. The number of successes is presented.
Measured: Baseline and 1 to 4-weeks post-start of treatment (SOT)
Long-term Durability of Average Pain Relief: Number of Participants With ≥ 50% Reduction in Average Pain Intensity
All participants were asked to complete daily diaries to record their average knee pain intensity during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The average pain score was calculated across the 7-day diary for each participant at baseline and at 3-, 6-, 9-, and 12-months post-start of treatment. Percent reduction was then calculated for each participant. To be considered a success, participants must have experienced ≥ 50% reduction in average knee pain. The number of successes is presented.
Measured: Baseline, 3-months post-start of treatment (SOT), 6-months post-SOT, 9-months post-SOT, 12-months post-SOT
Mean Pain Relief
All participants were asked to complete daily diaries to record their average knee pain intensity during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The mean pain score was calculated across the 7-day diary(s) for each participant at baseline, 1-4 weeks post-start of treatment (SOT), 5-8 weeks post-SOT, and at 3-, 6-, 9-, and 12-months post-SOT. The mean pain score is presented.
Measured: Baseline, 1 to 4-weeks post-start of treatment (SOT), 5 to 8-weeks post-SOT, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, and 12-months post-SOT
Pain Medication Usage
Participants recorded the amount/type of analgesics used in daily diaries. A blinded, third-party medication committee reviewed participants' diary medications for each time period to determine if each participant's analgesic usage changed. The committee determined whether there was No change (no change in dosage or change is not clinically meaningful to impact pain outcomes), an Increase (clinically meaningful increase in medication that would impact pain outcomes), or a Decrease (clinically meaningful decrease in medication that would impact pain outcomes) for each time period compared to baseline. The number of participants with a Decrease in analgesic medication usage for pain are reported. Participants that did not report any pain medications during the study were excluded from the analysis.
Measured: Baseline, 1 to 4 weeks post-start of treatment (SOT), and 5 to 8 weeks post-SOT, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, and 12-months post-SOT
Pain Catastrophizing Scale (PCS)
The Pain Catastrophizing Scale (PCS) questionnaire has 13 questions that assess rumination, magnification, and helplessness. Participants are asked to think back on painful experiences in the past and reflect on how often they had specific thoughts or feelings. Each of the 13 questions is scored on a 5-point scale where 0 represents "not at all," and 4 represents "all the time." The scores from each question were summed for each participant to provide a total PCS score, with a possible range from 0 to 52 with higher scores indicating a greater tendency to catastrophize pain (i.e. a higher score indicates a worse outcome). The mean score for each time point is presented.
Measured: Baseline (Visit 1), 4-weeks post-SOT (Visit 6), and 8-weeks post-SOT (Visit 10)
Patient Global Impression of Change (PGIC)
The Patient Global Impression of Change (PGIC) Survey asks participants to rate their improvement with treatment on a 7-point scale ranging from -3 to 0 to +3, where -3 represents "very much worse," 0 is "no change," and +3 represents "very much improved" as compared to before stimulation treatment. The participants combine all the components of their experience into one overall score. The mean score of each group was calculated for each time frame.
Measured: 4-weeks post-start of treatment (SOT)(Visit 6), 8-weeks post-SOT (Visit 10), 3-months post-SOT (Visit 11), 6-months post-SOT (Visit 12), 9-months post-SOT (Visit 13), and 12-months post-SOT (Visit 14)
Pain Interference: Number of Participants With ≥ 50% Reduction in Pain Interference
Question 9 of the Brief Pain Inventory-Short Form (BPI-9) is a 7-part question that assesses the level of interference that participants experience in their daily lives due to pain. The 7 categories are general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Participants were asked to rate how much their post-surgical knee pain interferes with each aspect on an 11-point numerical scale where 0 represents "Does Not Interfere" and 10 represents "Completely Interferes." The average of these 7 scores was calculated for each participant at each time point. Percent reduction was then calculated for each participant. To be considered a success, participants must have experienced ≥ 50% reduction in pain interference. The number of successes is presented.
Measured: Baseline (Visit 1), 8-weeks post-start of treatment (SOT) (Visit 10), 3-months post-SOT (Visit 11), 6-months post-SOT (Visit 12), 9-months post-SOT (Visit 13), and 12-months post-SOT (Visit 14)
Function (i.e., Physical Recovery)
The Western Ontario and McMaster University Osteoarthritis Index (WOMAC) questionnaire consists of 24 items that evaluate pain, stiffness, and physical functional disability. Each item is scored on an 11-point numerical rating scale from 0 to 10, where higher scores indicate greater pain, stiffness, and disability. For each participant, the scores from each of the 24 items were averaged to calculate the participant's total score, with a minimum score of 0 and a maximum score of 10. The mean total score was then calculated across participants and percent reduction was calculated for each time point. To be considered a success, participants must have experienced ≥ 33% reduction in their score. The number of successes is presented.
Measured: Baseline (Visit 1), 8-weeks post-start of treatment (SOT) (Visit 10), 3-months post-SOT (Visit 11), 6-months post-SOT (Visit 12), 9-months post-SOT (Visit 13), and 12-months post-SOT (Visit 14)
Six Minute Walk Test (6MWT)
The total distance that a participant could walk in 6 minutes was recorded, and participants unable to walk at all were given a score of 0 meters. The mean distance was then determined across participants. The baseline score was compared to the score at the specified intervals after start of therapy.
Measured: Baseline (Visit 1), 8-weeks post-start of treatment (SOT) (Visit 10), and 3-months post-SOT (Visit 11)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2020
- Study start6 Aug 2020
- Primary completion27 Jun 2024
- Study completion27 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 56 participants (actual)
Sponsor and investigators
- Lead sponsor
- SPR Therapeutics, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- United States Department of Defense
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04341948
- Sponsor's protocol ID
- 0150-CSP-000
- Other IDs
- CDMRP-OR170165
- Status last verified
- Aug 2025
- First submitted
- 7 Apr 2020
- Last updated
- 27 Aug 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Treatment of Post-Operative Pain Following Orthopedic Surgery With SPRINT® Peripheral Nerve Stimulation (PNS) System in a Randomized, Double-Blinded, Placebo-Controlled Trial
- ClinicalTrials.gov ID
- NCT04341948
- Acronym / sponsor ID
- 0150-CSP-000
- Conditions
- Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty, Partial Knee Replacement
- Keywords
- Pain, Postoperative, Musculoskeletal Diseases, Postoperative Complications, Nervous System Diseases, Pain, Neurologic Manifestations, Signs and Symptoms
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 56 participants (actual)
- Lead sponsor
- SPR Therapeutics, Inc.Industry (pharma, biotech, devices)
- Collaborators
- United States Department of Defense
- Study start
- 6 Aug 2020 (actual)
- Primary completion
- 27 Jun 2024 (actual)
- Study completion
- 27 Jun 2024 (actual)
- First posted
- 10 Apr 2020 (actual)
- Results
- Posted 27 Aug 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to gather information about how knee pain changes when small amounts of electricity are delivered to the nerves in the leg. This study will involve the use of a Peripheral Nerve Stimulation (PNS) System that is made by SPR Therapeutics (the sponsor of the study). The SPRINT PNS System was cleared by the FDA for up to 60 days of use in the back and/or extremities for the management of acute and chronic pain.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 1 (Treatment) | Active comparator | Device: SPRINT Peripheral Nerve Stimulation (PNS) SystemParticipants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks. |
| Group 2 (Control) | Sham comparator | Device: SPRINT Peripheral Nerve Stimulation (PNS) SystemParticipants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- At least 21 years old
- Underwent a 1. primary total knee replacement (TKR), 2. secondary/revision TKR or 3. Partial/unicompartmental knee replacement (PKR)
- Knee pain directly resulting from Knee Replacement surgery in affected knee
Key exclusion criteria (7 listed)
- Current high opioid use
- Body Mass Index (BMI) > 40 kg/m2
- Conditions with increased risk of infection
- Implanted electronic device
- History of bleeding or clotting disorder.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SPRINT Peripheral Nerve Stimulation (PNS) SystemAlso: SPRINT, SPRINT SystemThe SPRINT System delivers mild electrical stimulation to nerves in the affected limb. The SPRINT System includes two small wires (called "Leads") that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator). | Device | Group 1 (Treatment), Group 2 (Control) |
Primary outcome
Reduction in Average Pain Intensity: Number of Participants With ≥ 50% Reduction in Average Pain Intensity
Time frame: Baseline and 5 to 8 weeks post-Start of Treatment (SOT)
All participants were asked to complete daily diaries to record their average knee pain during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The average pain scores were calculated across the 7-day diary(s) at baseline and across weeks 5 to 8 post-start of treatment. Percent reduction was then calculated for each participant. To be considered a success, participants must have experienced ≥ 50% reduction in average knee pain. The number of successes is presented.
Study-Related Adverse Device Effects
Time frame: Up to 13 months for each Group 1 participant and up to 16 months for Group 2 participants that opted to cross over (time from baseline to last study visit)
At each study visit following the baseline assessment at Visit 1, participants were questioned if any changes in their medical status or condition have occurred since their previous visit. If the participant experienced a change that was a study-related adverse event, an Adverse Event Form was completed by the site. The number of participants that experienced at least one study-related adverse event is reported here. Adverse Events are reported by the trial phase in which they occurred: Group 1 Treatment (active stimulation), Group 2 Control (sham stimulation), and Group 2 Crossover Safety Set (active stimulation).
9 secondary outcomes
Reduction in Average Pain Intensity: Number of Participants With ≥ 50% Reduction in Average Pain Intensity
Time frame: Baseline and 1 to 4-weeks post-start of treatment (SOT)
Long-term Durability of Average Pain Relief: Number of Participants With ≥ 50% Reduction in Average Pain Intensity
Time frame: Baseline, 3-months post-start of treatment (SOT), 6-months post-SOT, 9-months post-SOT, 12-months post-SOT
Mean Pain Relief
Time frame: Baseline, 1 to 4-weeks post-start of treatment (SOT), 5 to 8-weeks post-SOT, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, and 12-months post-SOT
Pain Medication Usage
Time frame: Baseline, 1 to 4 weeks post-start of treatment (SOT), and 5 to 8 weeks post-SOT, 3-months post-SOT, 6-months post-SOT, 9-months post-SOT, and 12-months post-SOT
Pain Catastrophizing Scale (PCS)
Time frame: Baseline (Visit 1), 4-weeks post-SOT (Visit 6), and 8-weeks post-SOT (Visit 10)
Patient Global Impression of Change (PGIC)
Time frame: 4-weeks post-start of treatment (SOT)(Visit 6), 8-weeks post-SOT (Visit 10), 3-months post-SOT (Visit 11), 6-months post-SOT (Visit 12), 9-months post-SOT (Visit 13), and 12-months post-SOT (Visit 14)
Pain Interference: Number of Participants With ≥ 50% Reduction in Pain Interference
Time frame: Baseline (Visit 1), 8-weeks post-start of treatment (SOT) (Visit 10), 3-months post-SOT (Visit 11), 6-months post-SOT (Visit 12), 9-months post-SOT (Visit 13), and 12-months post-SOT (Visit 14)
Function (i.e., Physical Recovery)
Time frame: Baseline (Visit 1), 8-weeks post-start of treatment (SOT) (Visit 10), 3-months post-SOT (Visit 11), 6-months post-SOT (Visit 12), 9-months post-SOT (Visit 13), and 12-months post-SOT (Visit 14)
Six Minute Walk Test (6MWT)
Time frame: Baseline (Visit 1), 8-weeks post-start of treatment (SOT) (Visit 10), and 3-months post-SOT (Visit 11)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
10 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SPRINT Peripheral Nerve Stimulation (PNS) System in people with Postoperative Pain and Total Knee Replacement, run by SPR Therapeutics, Inc. at 10 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 10 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Aug 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction in Average Pain Intensity: Number of Participants With ≥ 50% Reduction in Average Pain Intensity (time frame: Baseline and 5 to 8 weeks post-Start of Treatment (SOT)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2025.